Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? - PubMed (original) (raw)
Clinical Trial
. 2010 Mar 30;74(13):1033-40.
doi: 10.1212/WNL.0b013e3181d7d651. Epub 2010 Mar 3.
Affiliations
- PMID: 20200338
- DOI: 10.1212/WNL.0b013e3181d7d651
Clinical Trial
Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?
F Barkhof et al. Neurology. 2010.
Abstract
Background: Ibudilast is a phosphodiesterase inhibitor influencing inflammation and neurodegeneration in multiple sclerosis (MS). This study evaluated the safety, tolerability, and effects on MRI parameters of 2 different doses of ibudilast in relapsing forms of MS.
Methods: In this multicenter, double-blind, phase 2 trial, patients with relapsing MS and gadolinium-enhancing lesions were randomly assigned 1:1:1 to receive 30 or 60 mg ibudilast or placebo every day for 12 months. The primary endpoint was the cumulative number of newly active lesions on bimonthly brain MRI over 12 months. Secondary endpoints included relapse rate, change in Expanded Disability Status Scale (EDSS) score, T2-hyperintense and T1-hypointense lesion volumes, and percent brain volume change (PBVC).
Results: A total of 297 patients were randomized in 19 centers. During the first 12 months, the mean number of active lesions and relapse rate did not differ between treatment arms. A reduction in PBVC (p = 0.04) was found in the 60-mg group (0.8%) compared with placebo (1.2%). Post hoc analysis showed a reduction in the proportion active lesions that evolved into persistent black holes for the 60-mg (0.14; p = 0.004) and 30-mg (0.17; p = 0.036) groups compared with the placebo group (0.24). Over 2 years, there were fewer patients (p = 0.026) with confirmed progression on the EDSS. Treatment with ibudilast was generally safe and well tolerated.
Conclusion: Ibudilast showed no beneficial effect on the rate of newly active lesions and relapses. However, preliminary evidence suggests that ibudilast seems to act in a neuroprotective fashion as measured by 2 independent MRI outcomes, with a possible beneficial clinical effect on disability progression.
Classification of evidence: This interventional study provides Class III evidence on the effect of ibudilast on disease activity.
Comment in
- Primary neuroprotection: the Holy Grail of multiple sclerosis therapy.
Fox RJ. Fox RJ. Neurology. 2010 Mar 30;74(13):1018-9. doi: 10.1212/WNL.0b013e3181d6b165. Epub 2010 Mar 3. Neurology. 2010. PMID: 20200341 No abstract available. - Epstein-Barr virus, 9.4 T MRI and phosphodiesterase inhibitors in multiple sclerosis.
Strupp M. Strupp M. J Neurol. 2010 May;257(5):860-2. doi: 10.1007/s00415-010-5571-y. J Neurol. 2010. PMID: 20419309 No abstract available.
Similar articles
- Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.
Lublin FD, Bowen JD, Huddlestone J, Kremenchutzky M, Carpenter A, Corboy JR, Freedman MS, Krupp L, Paulo C, Hariri RJ, Fischkoff SA. Lublin FD, et al. Mult Scler Relat Disord. 2014 Nov;3(6):696-704. doi: 10.1016/j.msard.2014.08.002. Epub 2014 Aug 29. Mult Scler Relat Disord. 2014. PMID: 25891548 Clinical Trial. - Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M. Togha M, et al. Mult Scler. 2010 Jul;16(7):848-54. doi: 10.1177/1352458510369147. Epub 2010 May 20. Mult Scler. 2010. PMID: 20488825 Clinical Trial. - Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ, Figgitt DP. Scott LJ, et al. CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010. CNS Drugs. 2004. PMID: 15089110 Review. - Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ. Fox EJ. Clin Ther. 2006 Apr;28(4):461-74. doi: 10.1016/j.clinthera.2006.04.013. Clin Ther. 2006. PMID: 16750460 Review.
Cited by
- Cuprizone-Induced Neurotoxicity in Human Neural Cell Lines Is Mediated by a Reversible Mitochondrial Dysfunction: Relevance for Demyelination Models.
Martínez-Pinilla E, Rubio-Sardón N, Villar-Conde S, Navarro G, Del Valle E, Tolivia J, Franco R, Navarro A. Martínez-Pinilla E, et al. Brain Sci. 2021 Feb 22;11(2):272. doi: 10.3390/brainsci11020272. Brain Sci. 2021. PMID: 33671675 Free PMC article. - Disease Modifying Strategies in Multiple Sclerosis: New Rays of Hope to Combat Disability?
Bellanca CM, Augello E, Mariottini A, Bonaventura G, La Cognata V, Di Benedetto G, Cantone AF, Attaguile G, Di Mauro R, Cantarella G, Massacesi L, Bernardini R. Bellanca CM, et al. Curr Neuropharmacol. 2024;22(8):1286-1326. doi: 10.2174/1570159X22666240124114126. Curr Neuropharmacol. 2024. PMID: 38275058 Free PMC article. Review. - Emerging therapies to target CNS pathophysiology in multiple sclerosis.
Oh J, Bar-Or A. Oh J, et al. Nat Rev Neurol. 2022 Aug;18(8):466-475. doi: 10.1038/s41582-022-00675-0. Epub 2022 Jun 13. Nat Rev Neurol. 2022. PMID: 35697862 Review. - Inhibition of phosphodiesterase-4 promotes oligodendrocyte precursor cell differentiation and enhances CNS remyelination.
Syed YA, Baer A, Hofer MP, González GA, Rundle J, Myrta S, Huang JK, Zhao C, Rossner MJ, Trotter MW, Lubec G, Franklin RJ, Kotter MR. Syed YA, et al. EMBO Mol Med. 2013 Dec;5(12):1918-34. doi: 10.1002/emmm.201303123. Epub 2013 Oct 21. EMBO Mol Med. 2013. PMID: 24293318 Free PMC article. - Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives.
Ontaneda D, Fox RJ, Chataway J. Ontaneda D, et al. Lancet Neurol. 2015 Feb;14(2):208-23. doi: 10.1016/S1474-4422(14)70264-9. Lancet Neurol. 2015. PMID: 25772899 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials